Replies to post #128947 on Biotech Values

[genisi]

ABT’s all-oral HCV combo(s)

The components will likely include ABT-450 (a PI), ABT-267 (an NS5A inhibitor), and one of the non-nukes (ABT-072 or ABT-333).

In light of #msg-74608528 I will not be surprised if only 333 is moved to phase III.